SCHEMBL4416565

SCHEMBL4416565

COC(=O)CCOC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.47
HPGD P15428 1/20 0.46
ALDH1A1 P00352 2/20 0.44
PDE4A P27815 2/20 0.44
PDE4B Q07343 2/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
RECQL P46063 1/20 0.44
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPN6 P29350 1/20 0.43
GPR119 Q8TDV5 4/20 0.43
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24476657 0.90 ALDH1A1 (0.44) EPHX1HPGDALDH1A1PDE4APDE4B
SCHEMBL21998027 0.86 HPGD (0.44) EPHX1HPGDALDH1A1PDE4APDE4B
SCHEMBL4035282 0.86 HPGD (0.48) EPHX1HPGDPDE4APDE4BPDE4C
SCHEMBL3142012 0.86 EPHX1 (0.49) EPHX1HPGDALDH1A1PDE4APDE4B
SCHEMBL26094030 0.86 NR1H2 (0.46) EPHX1HPGDALDH1A1PDE4BPRMT5
SCHEMBL792038 0.84 HPGD (0.49) EPHX1HPGDALDH1A1PDE4APDE4B
SCHEMBL1576027 0.82 HPGD (0.50) EPHX1HPGDRECQLPTPN2PTPN1
SCHEMBL2149148 0.82 HPGD (0.50) EPHX1HPGDPDE4APDE4BPDE4C
SCHEMBL29575514 0.82 PRMT5 (0.42) EPHX1HPGDALDH1A1PDE4APDE4B
SCHEMBL6132702 0.82 HPGD (0.47) EPHX1HPGDPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085082-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2026-03-26 US disclosed
EP-4637760-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2025-10-29 EP disclosed
WO-2025072686-A1 KRAS G12D MUTATION TARGETING COMPOUNDS SUMMIT THERAPEUTICS INC. (US) 2025-04-03 WO disclosed
WO-2024137358-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2024-06-27 WO disclosed
WO-2024137358-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2024-06-27 WO disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
EP-1907383-A1 GPCR AGONISTS Prosidion Limited (GB) 2008-04-09 EP disclosed
WO-2007003960-A1 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 EPHX1 1312/4885HPGD 1902/4885ALDH1A1 1059/4885
US-20260085082-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM5C EPHX1 2884/4885HPGD 4013/4885ALDH1A1 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.